Becton, Dickinson and Company (NYSE:BDX) Issues FY 2025 Earnings Guidance

Becton, Dickinson and Company (NYSE:BDX) updated its FY 2025 earnings guidance on Wednesday. The company provided earnings per share guidance of 14.300-14.600 for the period, compared to the consensus earnings per share estimate of 14.350. The company issued revenue guidance of $21.7 billion-$21.9 billion, compared to the consensus revenue estimate of $21.9 billion.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on BDX shares. StockNews.com downgraded Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research report on Wednesday, December 18th. Piper Sandler raised their price target on Becton, Dickinson and Company from $275.00 to $280.00 and gave the company an “overweight” rating in a report on Tuesday, January 28th. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $283.00.

Becton, Dickinson and Company Price Performance

BDX stock traded up $2.65 during mid-day trading on Wednesday, hitting $245.07. 2,061,265 shares of the stock were exchanged, compared to its average volume of 2,046,401. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.17 and a quick ratio of 0.74. The stock has a market capitalization of $71.07 billion, a price-to-earnings ratio of 41.26, a PEG ratio of 1.80 and a beta of 0.40. The business has a fifty day moving average price of $231.33 and a 200 day moving average price of $234.02. Becton, Dickinson and Company has a 12 month low of $218.75 and a 12 month high of $251.99.

Becton, Dickinson and Company (NYSE:BDX) last issued its earnings results on Wednesday, February 5th. The medical instruments supplier reported $3.43 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.00 by $0.43. Becton, Dickinson and Company had a return on equity of 14.89% and a net margin of 8.55%. On average, sell-side analysts anticipate that Becton, Dickinson and Company will post 14.41 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, March 31st. Shareholders of record on Monday, March 10th will be given a dividend of $1.04 per share. The ex-dividend date is Monday, March 10th. This represents a $4.16 annualized dividend and a yield of 1.70%. Becton, Dickinson and Company’s payout ratio is currently 70.03%.

Becton, Dickinson and Company declared that its board has initiated a share repurchase plan on Tuesday, January 28th that permits the company to repurchase 10,000,000 outstanding shares. This repurchase authorization permits the medical instruments supplier to buy shares of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s management believes its shares are undervalued.

Insider Activity

In related news, EVP Roland Goette sold 638 shares of the company’s stock in a transaction that occurred on Monday, December 9th. The stock was sold at an average price of $219.03, for a total transaction of $139,741.14. Following the completion of the transaction, the executive vice president now owns 14,217 shares in the company, valued at $3,113,949.51. This represents a 4.29 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Michael David Garrison sold 2,838 shares of Becton, Dickinson and Company stock in a transaction on Thursday, December 19th. The shares were sold at an average price of $223.33, for a total transaction of $633,810.54. Following the completion of the sale, the executive vice president now owns 6,141 shares in the company, valued at approximately $1,371,469.53. This trade represents a 31.61 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 9,844 shares of company stock valued at $2,210,716. Insiders own 0.36% of the company’s stock.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.